Diabetologie und Stoffwechsel, Inhaltsverzeichnis Diabetologie und Stoffwechsel 2012; 7(5): 367-372DOI: 10.1055/s-0032-1325427 Editorial © Georg Thieme Verlag KG Stuttgart · New York Glucagon-like Peptide-1 (GLP-1): 25 Jahre Ansporn für die Diabetesforschung M. A. Nauck Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Bell GI, Sanchez-Pescador R, Laybourn PJ et al. Exon duplication and divergence in the human preproglucagon gene. Nature 1983; 304: 368-371 2 Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985; 28: 704-707 3 Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619 4 Holst JJ, Ørskov C, Vagn-Nielsen O et al. Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut. FEBS Letters 1987; 211: 169-174 5 Kreymann B, Williams G, Ghatei MA et al. Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 1987; 2: 1300-1304 6 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705 7 Brown JC. Gastric Inhibitory Polypeptide. Heidelberg: Springer-Verlag; 1982 8 Dupré J, Ross SA, Watson D et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 1973; 37: 826-828 9 Krarup T, Saurbrey N, Moody AJ et al. Effect of porcine gastric inhibitory polypeptide on ß-cell function in Type 1 and Type II diabetes mellitus. Metabolism: clinical and experimental 1988; 36: 677-682 10 Nauck MA, Heimesaat MM, Ørskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307 11 Vilsbøll T, Krarup T, Madsbad S et al. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45: 1111-1119 12 Suzuki S, Kawai K, Ohashi S et al. Reduced insulinotropic effects of glucagonlike peptide 1-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Diabetes 1990; 39: 1320-1325 13 Ebert R, Illmer K, Creutzfeldt W. Release of gastric inhibitory polypeptide (GIP) by intraduodenal acidification in rats and humans and abolishment of the incretin effect of acid by GIP-antiserum in rats. Gastroenterol 1979; 76: 515-523 14 Nauck MA, Schmidt WE, Ebert R et al. Insulinotropic properties of synthetic gastric inhibitory peptide in man: interactions with glucose, phenylalanin, and cholezystokinin-8. J Clin Endocrinol Metab 1989; 69: 654-662 15 Nauck MA, Bartels E, Ørskov C et al. Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects. Digestion 1992; 52: 214-221 16 Ebert R, Creutzfeldt W. Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution. Diabetologia 1980; 19: 198-204 17 Ebert R, Creutzfeldt W. Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia. Acta Diabetol Lat 1989; 26: 1-15 18 Nauck MA, Kleine N, Ørskov C et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744 19 Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246 20 Willms B, Werner J, Holst JJ et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 1996; 81: 327-332 21 Nauck MA, Wollschläger D, Werner J et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996; 39: 1546-1553 22 Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673 23 Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol (Endocrinol Metab) 1997; 273: E981-E988 24 Gutniak MK, Linde B, Holst JJ et al. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 1994; 17: 1039-1044 25 Ritzel R, Ørskov C, Holst JJ et al. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725 26 Nauck MA, Wollenschläger D, Werner J et al. Pharmacokinetic, insulinotropic, and glucagonostatic prosperties of GLP-1 after subcutaneous injection in healthy volunteers. Diabetologia 1995; 38: 720-725 27 Deacon CF, Nauck MA, Toft-Nielsen M et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131 28 Deacon CF, Hughes TE, Holst JJ. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 1998; 47: 764-769 29 Mentlein R. Dipeptidyl-peptidase IV (CD26) – role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24 30 Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829-835 31 Deacon CF, Pridal L, Klarskov L et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol (Endocrinol Metab) 1996; 271: E 458-E 464 32 DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100 33 Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90 34 Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250 35 Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes melllitus. Am Health Syst Pharm 2005; 62: 173-181 36 Elbrønd B, Jakobsen G, Larsen S et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404 37 Agersø H, Jensen LB, Elbrond B et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202 38 Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47 39 Kim D, MacConell L, Zhuang D et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007; 30: 1487-1493 40 Nauck MA, Kemmeries G, Holst JJ et al. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565 . Epub 2011/03/25 41 Christensen M, Knop FK, Holst JJ et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Drugs 2009; 12: 503-513 42 Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103-112 . Epub 2010/12/09 43 Arnolds S, Dellweg S, Clair J et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010; 33: 1509-1515 44 Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008; 151: 123-129 45 Nauck MA, Meier JJ. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 2005; 124 (Suppl. 01) 135-148 46 Creutzfeldt W. The incretin concept today. Diabetologia 1979; 16: 75-85 47 Vardarli I, Nauck MA, Köthe LD et al. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as “isoglycemic” intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 945-954 . Epub 2011/01/18 48 Muscelli E, Casolaro A, Gastaldelli A et al. Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2012; 97: 2818-2826 . Epub 2012/06/12 49 Göke R, Fehmann HC, Linn T et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268: 19650-19655 50 Thorens B, Porret A, Buhler L et al. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993; 42: 1678-1682 51 Kutscherauer G, Bedorf A, Nocolaus M et al. The DPP-4 inhibitor sitagliptin improves glucose tolerance in type 2 diabetes mellitus involving GLP-1 dependent and GLP-1 independent pathways (abstract). Diabetologia 2009; 52 (Suppl. 01) S 9 52 Nauck MA, Kind J, Deacon CF et al. Blocking GLP-1 action with exendin (9-39) to determine the contribution of GLP-1 to the inhibitory effects of the DPP-4 inhibitor vildagliptin (abstract). Diabetologia 2011; 54 (Suppl. 01) S 108 53 Ban K, Noyan-Ashraf MH, Hoefer J et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350. Epub 2008/04/23 . Epub 2008/04/23 54 Li Y, Perry T, Kindy MS et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009; 106: 1285-1290 . Epub 2009/01/24
